Last evening at #ESC2025 in Madrid 🇪🇸 – reflecting on an successful congress full of knowledge, exchange, and great discussions. It was a pleasure to meet Prof. Seferović and take a photo together. 📸 #ESC2025 #Madrid #Cardiology #MedicalConference #heartfailure #MedUniVienna

🔴 #EACVI Summit 2025 – 10th Edition | Valencia, Spain 🇪🇸 The European Association of Cardiovascular Imaging is proud to host the 10th edition of the #EACVI Summit with National Societies on 29–30 May 2025 in Valencia. Since 2009, this biennial summit has served as a vital

Patient:innen zu mehr Gesundheit zu verhelfen und in einem gut eingespielten Team zu arbeiten, das freut @g_heitzinger besonders. Lesen Sie mehr über die Studie unseres #ResearcheroftheMonth zur sekundären Trikuspidalklappeninsuffizienz. ➡ https://t.co/tkc6V3qLeV

In secondary #tricuspid regurgitation (STR), high comorbidity burden is common and complicates patient management. New study in #EHJCVI using #MachineLearning validated the most powerful predictors of all-cause mortality in #heartfailure pts with STR 🧵 https://t.co/TX9yhTdra7

Advancing our risk stratification of patients with tricuspid regurgitation using the most relevant markers of increased mortality. Congratulations to @g_heitzinger @ggoliasch @pe_bartko for this elegant study using #MachineLearning in #EHJCVI https://t.co/mdzcfi2pNy

Secondary TR in HF: ☝️Prognostic significance across the spectrum of HF. ☝️Consider the systemic implication of sTR! 🤔What do we know about the RV pre- & after-load interplay in regard to #sTR treatment @escardio @HeartFailure2023 @ESC_HFA @ValveDisease @MariannaAdamo1

How are LV filling pressures affected by #CTEPH? How does this affect patient outcomes? In this insightful work, Drs. @ChristianGerges, Lang, & colleagues evaluate this question w/ important implications for #CardioTwttier & #PulmTwitter providers: https://t.co/gm2cWiSFaq #JACC

Had a lot of fun writing this with @ClemensGangl - Digital Health - High Tech or High Touch? #DigitalHealth #DigitalMedicine #EHealth #AI #machinelearning #CardioTwitter

Einen herzlichen Dank an Dr. Gregor Heitzinger @meduniwien @KardiologieWien für den informativen Vortrag über die Funktion der Herzklappen und die häufigsten Herzklappenerkrankungen. Rechtzeitig erkannt sind sie gut behandelbar, deshalb ist es wichtig, die Symptome zu kennen‼️

@KardiologieWien @MedUni_Wien @escardio @krychtiukmd @CHengstenbergMD @ValveDisease @pe_bartko @noemi_pavo @billrothhaus @wien_wissen @ICOSociety @Uro_MedUniWien @aekwien Thank you, Siva!

We congratulate @BerglerKlein from our @KardiologieWien @MedUni_Wien for her important role within the @escardio task force for #CardioOncology and the composition of the 2022 #guidelines presented at the world leading Cardiology Congress #ESCCongress https://t.co/2v8TnC9stO

Dual pathology cardiac amyloidosis and mitral regurgitation is frequent and carries worse outcomes following mitral valve repair @amyloidosis @mitral @g_heitzinger @pe_bartko @a_kammerlander @m_koschutnik @JMascherbauer @KardiologieWien AddThis | Home

Im Rahmen der Langen Nacht der Forschung können Sie eine von unseren @KardiologieWien ExpertInnen live-kommentierte minimal-invasive Herklappen-Implantation verfolgen! Fr 20.5. 18:00 @MedUni_Wien / AKH Hörsaalzentrum https://t.co/dHo4L9skJd

In a #whyCMR analysis, Rene Rettl and coworkers from @MedUni_Wien showed that treatment with tafamidis delays myocardial amyloid progression in ATTR-CM patients. #amyloidosis #Cardiotwitter https://t.co/FIuuGfQJc0

Topological mapping in secondary MR (sMR): #echofirst analysis shows importance of role of LA. Highest mortality in “small LV cavity” cluster. https://t.co/p71Eta3txG #vhdMR #cvVHD #JACCIMG #CardioTwitter #cvImaging #HFrEF @ValveDisease @pe_bartko @g_heitzinger @ggoliasch

What are the key morphological and functional features in secondary mitral regurgitation? @pe_bartko, @g_heitzinger, @ggoliasch et al from our @ValveDisease group present exciting novel data in @JACCJournals https://t.co/JZG0CROvaB

Häufig unterschätzt: #Mitralklappeninsuffizienz. Eine Studie der #MedUniWien und des #AKHWien erforscht neue Therapiemöglichkeiten von RisikopatientInnen mit Herzklappenfehlern:

"Valve repair strategies are rarely used across the entire heart failure spectrum with severe mitral regurgitation despite availability of minimal invasive and low risk options." New #BMJResearch by @ggoliasch and colleagues https://t.co/zJzbslP3Kf

Secondray #mitralregurgitation is prevalent across the heart failure spectrum! 📈 - 10% overall severe MR among #heartfailure patients🏥 - prevalence: #HFrEF> #HFmrEF > #HFpEF! - poor prognosis☠️ in any #HF subtype! https://t.co/VqLsTHckmq

Congratulations to our @ValveDisease group around @pe_bartko @ggoliasch @g_heitzinger et al for this important observational analysis on the burden, treatment use, and outcome of secondary mitral regurgitation published in @bmj_latest https://t.co/fD7VdiAVJM